B. Metzler seel. Sohn & Co. AG acquired a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 9,241 shares of the company's stock, valued at approximately $2,262,000.

• Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out

Several other institutional investors and hedge funds have also recently modified their holdings of AXSM. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Axsome Therapeutics by 4.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,923 shares of the company's stock worth $2,557,000 after purchasing an additional 1,002 shares in the last quarter. Jones Financial Companies Lllp increased its stake in Axsome Therapeutics by 2,407.9% during the 1st quarter. Jones Financial Companies Lllp now owns 7,624 shares of the company's stock worth $889,000 after buying an additional 7,320 shares during the period. Goldman Sachs Group Inc. increased its stake in Axsome Therapeutics by 38.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 301,718 shares of the company's stock worth $35,189,000 after buying an additional 84,151 shares during the period. Caxton Associates LLP acquired a new stake in Axsome Therapeutics during the 1st quarter worth approximately $307,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Axsome Therapeutics by 29.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 74,892 shares of the company's stock worth $8,735,000 after buying an additional 17,250 shares in the last quarter. Hedge funds and other institutional investors own 81.49% of the company's stock.

Insider Buying and Selling at Axsome Therapeutics

In related news, CFO Nick Pizzie sold 33,000 shares of the company's stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $240.09, for a total value of $7,922,970.00. Following the completion of the transaction, the chief financial officer directly owned 42,867 shares of the company's stock, valued at $10,291,938.03. This represents a 43.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Roger Jeffs sold 286 shares of the stock in a transaction that occurred on Wednesday, June 10th. The shares were sold at an average price of $246.18, for a total transaction of $70,407.48. Following the completion of the transaction, the director owned 58,653 shares in the company, valued at $14,439,195.54. This represents a 0.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 200,766 shares of company stock worth $46,685,646. 20.60% of the stock is currently owned by corporate insiders.

Axsome Therapeutics Stock Performance

• 5 medical stocks growing earnings by triple digits

NASDAQ:AXSM opened at $207.77 on Friday. Axsome Therapeutics, Inc. has a 12 month low of $112.90 and a 12 month high of $260.19. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.43 and a quick ratio of 1.34. The firm has a market capitalization of $10.88 billion, a PE ratio of -55.41 and a beta of 0.65. The business's fifty day moving average price is $232.13 and its 200 day moving average price is $206.02.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.89) by ($0.10). The business had revenue of $218.38 million for the quarter, compared to analysts' expectations of $221.11 million. Axsome Therapeutics had a negative return on equity of 265.55% and a negative net margin of 24.68%. On average, sell-side analysts anticipate that Axsome Therapeutics, Inc. will post -2.78 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

• Struggling Axsome Stock Could Bounce Back on Drug Trial Success

A number of research firms have recently weighed in on AXSM. Piper Sandler reaffirmed an "overweight" rating and set a $258.00 price objective on shares of Axsome Therapeutics in a research report on Monday, May 4th. BMO Capital Markets assumed coverage on Axsome Therapeutics in a report on Monday, July 20th. They issued an "outperform" rating and a $310.00 target price for the company. Zacks Research raised Axsome Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 18th. Morgan Stanley upped their price target on Axsome Therapeutics from $242.00 to $251.00 and gave the stock an "equal weight" rating in a report on Tuesday, August 11th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Axsome Therapeutics in a research report on Friday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Axsome Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $267.60.

Check Out Our Latest Analysis on Axsome Therapeutics

Axsome Therapeutics Company Profile

(Free Report)

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome's pipeline includes several late-stage and approved product candidates.

Read More

• Five stocks we like better than Axsome Therapeutics
• 2 Biotech Stocks Shaping Up for Major Breakouts
• 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
• 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
• Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Axsome Therapeutics Right Now?

Before you consider Axsome Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.

While Axsome Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here